Veracyte Valuation
| VCYT Stock | USD 41.11 1.52 3.84% |
At this time, the company appears to be fairly valued. Veracyte has a current Real Value of $42.54 per share. The regular price of the company is $41.11. Our model measures the value of Veracyte from inspecting the company fundamentals such as Return On Equity of -0.0083, shares outstanding of 77.5 M, and Operating Margin of 0.11 % as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Veracyte's price fluctuation is very steady at this time. Calculation of the real value of Veracyte is based on 3 months time horizon. Increasing Veracyte's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Veracyte's intrinsic value may or may not be the same as its current market price of 41.11, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 41.11 | Real 42.54 | Hype 41.26 | Naive 39.03 |
The intrinsic value of Veracyte's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Veracyte's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Veracyte helps investors to forecast how Veracyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Veracyte more accurately as focusing exclusively on Veracyte's fundamentals will not take into account other important factors: Veracyte Total Value Analysis
Veracyte is at this time anticipated to have valuation of 2.93 B with market capitalization of 3.19 B, debt of 12.63 M, and cash on hands of 170.11 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Veracyte fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.93 B | 3.19 B | 12.63 M | 170.11 M |
Veracyte Investor Information
About 99.0% of the company outstanding shares are owned by institutional investors. The book value of Veracyte was at this time reported as 15.18. The company recorded a loss per share of 0.13. Veracyte had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Veracyte's historical financial statements, Veracyte is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Veracyte Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Veracyte has an asset utilization ratio of 32.38 percent. This implies that the Company is making $0.32 for each dollar of assets. An increasing asset utilization means that Veracyte is more efficient with each dollar of assets it utilizes for everyday operations.Veracyte Ownership Allocation
The majority of Veracyte outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Veracyte to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Veracyte. Please pay attention to any change in the institutional holdings of Veracyte as this could imply that something significant has changed or is about to change at the company.Veracyte Profitability Analysis
The company reported the previous year's revenue of 361.05 M. Net Loss for the year was (74.4 M) with profit before overhead, payroll, taxes, and interest of 296.96 M.About Veracyte Valuation
The stock valuation mechanism determines Veracyte's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Veracyte based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Veracyte. We calculate exposure to Veracyte's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Veracyte's related companies.The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people.
Veracyte Growth Indicators
Investing in growth stocks can be very risky. If the company such as Veracyte does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 72.6 M | |
| Forward Price Earnings | 43.4783 |
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.